Journal
ARCHIVES OF PHARMACAL RESEARCH
Volume 35, Issue 11, Pages 1979-1988Publisher
PHARMACEUTICAL SOC KOREA
DOI: 10.1007/s12272-012-1115-6
Keywords
Embryonic stem cells; Cardiogenesis; Peptidomimetic compounds; Ischemic heart disease
Categories
Funding
- Research Program for NRL [R0A-2007-000-20016-0]
- Ministry of Education, Science & Technology, Korea [M1074800306-08N4800]
- JW Pharmaceutical Corp.
Ask authors/readers for more resources
Embryonic stem (ES) cells may be used as an alternative source of functionally intact cardiomyocytes for ischemic heart disease. Several natural and synthetic small molecules have been identified as useful tools for controlling and manipulating stem cell renewal and differentiation. Currently, there is an urgent requirement for novel small molecules that specifically induce differentiation of stem cells into cardiomyocytes. To identify compounds that promote cardiomyogenesis of stem cells, cell-based screening of a peptidomimetic small-molecule library was carried out. A series of beta-turn peptidomimetic compounds, including CW209E, increased the expression of alpha-MHC promoter-driven enhanced green fluorescent protein (EGFP) and ratio of beating embryoid bodies (EBs) without inducing cytotoxicity in mouse embryonic stem cells. CW209E also increased the number of beating EBs in human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs). Thus, this chemical compound should be useful for elucidation of the molecular pathway of cardiogenesis and generation of cardiomyocytes ex vivo, which can be further applied for experimental or clinical cell therapy for ischemic heart diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available